CV
Dr. rer. nat. Gianmaria Liccardi
Academic education
2006 – 2011 PhD in Molecular Oncology, University College London (UCL), London, UK
2003 – 2004 MSc Molecular Medicine, Imperial College, London, UK
2000 – 2003 BSc Molecular Genetics in Biotechnology, University of Sussex, Brighton, UK
Scientific degrees
2011 PhD, in Molecular Oncology, University College London, UK: EGFR modulation of chemotherapy and radiotherapy
2004 Master with distinction in Molecular Medicine Identification of the Yaa mutation in BXSB Lupus erythematosus Imperial College London, UK
2003 BSc (Hons) first class, University of Sussex Characterization of the P27kip1 phosphorylation in the regulation of RB
Scientific career
2022 - present Honorary Lecturer in Cell & Developmental Biology, University College, London, UK
2022-present Lecturer MSSO, University of Cologne, Germany
03/2021 - present Junior Group Leader, Center for Biochemistry, University of Cologne, Cologne,
2020 - 2021 Senior Post-doctoral Fellow, CECAD Research Centre, University of Cologne
2012 - 2019 Post-doctoral Fellow, The Institute of Cancer Research, London, UK
2018 - present Editorial board member, Editor of Cell Death Disease, Nature Publishing group
2018 - present Lecturer for MSc Oncology, The Institute of Cancer Research, London, UK
2011 - 2012 Post-doctoral Fellow, UCL Cancer Institute, UCL, London, UK
2006 - 2011 PhD student, UCL Cancer Institute, UCL, London, UK
2010-present Lecturer, Faculty of Life Science, UCL, London, UK
2010 - 2012 Lecturer for MSc Cancer, UCL Cancer Institute, UCL, London, UK
2006 - 2010 Teaching Assistant, Faculty of Life Science, UCL, London, UK
2005 - 2006 Research Assistant, Imperial College, London, UK
2003 - 2004 MSc student, Imperial College, London, UK
Contact Information
Dr. rer. nat. Gianmaria Liccardi
Junior Research Group Leader Oncology
University of Cologne
Center of Biochemistry
10 most relevant publications
- Pang J, Al-Ani AH, Patel KM, Young SN, Kong I, Chen J jin, Barrios M, Rickard JA, Chen S, Foroughi S, Cawthorne W, Jacobsen A v., Jois A, Weir AL, Whitehead LW, Rajasekhar P, Horne CR, Azeez I, Tan T, Liang W, Sivanesan S, Metz A, Patwardhan A, Shea N, Iyngkaran G, Schneider D, Elford AT, Beattie W, Macrae F, Liccardi G, Walczak H, Zhang Y, Sieber OM, Spelman T, Giulino-Roth L, Hawkins ED, Rogers KL, Bowden R, Nicholson SE, Lawlor KE, Christensen B, Samson AL, Vince JE, Murphy JM. A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease. (Preprint posted online November 13, 2024. doi:10.1101/2024.11.13.623307.) Science. in press
- Tishina S, Dahlhaus A, Manik M, Mulalic L, Murr J, Kotliar M, Rakhsh-Khorshid H, Kostopoulou M, Hocher F, Stroh J, Beck J, Williams RM, Balta GG, Liu F, Abdallah AT, Bebber CM, Reese M, Lim JKM, Quaas A, Brägelmann J, Pasparakis M, Beleggia F, Balachandran S, Trauzold A, Liccardi G, Astsaturov I, Reichert M, Androulidaki A, von Karstedt S. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Nat Commun. 2026;17(1):5288. doi:10.1038/s41467-026-73189-8
- Kelepouras K, Saggau J, Bonasera D, Kiefer C, Locci F, Rakhsh-Khorshid H, Grauvogel L, Varanda AB, Peifer M, Loricchio E, Montinaro A, Croon M, Trifunovic A, Prencipe G, Insalaco A, de Benedetti F, Walczak H, Liccardi G. STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD. Nature. 2025;647(8090):735-746. doi:10.1038/s41586-025-09536-4
- Kelepouras K, Saggau J, Varanda AB, Zrilic M, Kiefer C, Rakhsh-Khorshid H, Lisewski I, Uranga-Murillo I, Arias M, Pardo J, Tonnus W, Linkermann A, Annibaldi A, Walczak H, Liccardi G. The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo. Cell Death Differ. 2024;31(7):897-909. doi:10.1038/s41418-024-01313-6
- Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, Krekó M, Azami S, Montinaro A, Wang Y, Nikolov V, Kaiser L, Bonasera D, Saggau J, Scholz T, Schmitt A, Beleggia F, Reinhardt HC, George J, Liccardi G, Walczak H, Tóvári J, Brägelmann J, Montero J, Sos ML, Őrfi L, Peltzer N. CDK9 inhibition as an effective therapy for small cell lung cancer. Cell Death Dis. 2024;15(5):345. doi:10.1038/s41419-024-06724-4
- Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Torres Fernández LA, Saggau J, Bonasera D, Kiljan M, Gozum G, Lichius L, Cai J, Niu L na, Caiaffa MI, Herter JM, Walczak H, Liccardi G, Grüll H, Büttner R, Bosco G, George J, Thomas RK, Bozek K, Reinhardt HC, Herter-Sprie GS. A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. J Cancer Res Clin Oncol. 2024;150(11):496. doi:10.1007/s00432-024-05942-9
- Imai T, Lin J, Kaya GG, Ju E, Kondylis V, Kelepouras K, Liccardi G, Kim C, Pasparakis M. The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. Immunity. 2024;57(7):1497-1513.e6. doi:10.1016/j.immuni.2024.04.016
- Smith HG, Jamal K, Dayal JH, Tenev T, Kyula-Currie J, Guppy N, Gazinska P, Roulstone V, Liccardi G, Davies E, Roxanis I, Melcher AA, Hayes AJ, Inman GJ, Harrington KJ, Meier P. RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Mol Med. 2020;12(6):EMMM201910979. doi:10.15252/emmm.201910979
- Ruiz EJ, Diefenbacher ME, Nelson JK, Sancho R, Pucci F, Chakraborty A, Moreno P, Annibaldi A, Liccardi G, Encheva V, Mitter R, Rosenfeldt M, Snijders AP, Meier P, Calzado MA, Behrens A. LUBAC determines chemotherapy resistance in squamous cell lung cancer. Journal of Experimental Medicine. 2019;216(2):450-465.doi:10.1084/jem.20180742
- Anderton H, Bandala-Sanchez E, Simpson DS, Rickard JA, Ng AP, di Rago L, Hall C, Vince JE, Silke J, Liccardi G*#, Feltham R*#. RIPK1 prevents TRADD-driven, but TNFR1 independent, apoptosis during development. Cell Death Differ. 2019;26(5):877-889. doi:10.1038/s41418-018-0166-8 *Shared last authors, #co-corresponding
